Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 22:11:213-225.
doi: 10.2147/JBM.S236789. eCollection 2020.

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)

Guenter Auerswald  1 , Claudia Djambas Khayat  2 , Oleksandra Stasyshyn  3 , Genadi Iosava  4 , Irina Romashevskaya  5 , Marta Julia López  6 , Wilfried Seifert  7 , Tobias Rogosch  7
Affiliations

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)

Guenter Auerswald et al. J Blood Med. .

Abstract

Purpose: Formulation V (VONCENTO®) is a plasma-derived high-concentration/low-volume, high-purity von Willebrand factor (VWF)/factor VIII (FVIII) concentrate, originally indicated for von Willebrand disease (VWD) in adults and adolescents. This multicenter, open-label study (SWIFTLY-VWD) evaluated the pharmacokinetics (PK), as well as hemostatic efficacy and safety, of Formulation V in pediatric patients (<12 years) with severe VWD requiring treatment or prophylaxis of bleedings.

Methods: PK investigations were performed following one dose of Formulation V at Day 1 and 180. Nonsurgical bleeds were analyzed, while hemostatic efficacy was graded as excellent/good/moderate/none. Safety assessments included adverse events, and presence of VWF and/or FVIII inhibitors.

Results: Formulation V was administered as on-demand (N=13) or prophylaxis therapy (N=4) for 12 months (<6 years, N=9; 6 to <12 years, N=8). PK parameters for VWF markers were generally comparable to adults but showed lower VWF:ristocetin cofactor (RCo) exposure. Incidence of major bleeds was lower for prophylaxis (3.3%) than on-demand therapy (27.1%); joint bleeds were also lower (3.3% vs 11.5%, respectively). Investigator-reported excellent/good hemostatic efficacy against nonsurgical bleeds was 100%. No clinically relevant differences in PK, hemostatic efficacy, or safety were observed between age-groups (<6 years and 6 to <12 years). Formulation V was well tolerated. Adverse events were mild-moderate and consistent with the adult safety profile. No cases of anaphylactic reactions or angioedema, development of FVIII/VWF inhibitors, thromboembolic events, or viral infections were reported.

Conclusion: This study provides evidence for use of Formulation V to treat and prevent bleeding in pediatric patients with severe VWD, and led to the European approval of Formulation V in children.

Keywords: clinical trial; pediatrics; prophylaxis; von Willebrand disease; von Willebrand factor-factor VIII concentrate.

PubMed Disclaimer

Conflict of interest statement

GA has received reimbursements for attending symposia/congresses and/or honoraria for speaking and/or consulting and/or funds for research support from CSL Behring. OS has received honoraria from Novo Nordisk, Takeda, and CSL Behring, and declares membership of speaker bureaus for Novo Nordisk, Takeda and Pfizer. WS and TR are employees of CSL Behring. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Patient disposition. Notes: a14 subjects eligible for analysis. b5 subjects eligible for analysis. Abbreviations: PK, pharmacokinetics; VWD, von Willebrand disease.
Figure 2
Figure 2
Mean (SD) concentration profiles (IU/mL) of baseline-adjusted VWF:RCo, VWF:Ag, VWF:CB, and FVIII:C in patients below the age of 12 (initial PK [N=14], repeat PK [N=8]). Red dashed line: lower limit of quantitation (VWF:RCo: 0.1 IU/mL; VWF:Ag, VWF:CB: 0.025 IU/mL; FVIII:C: 0.008 IU/mL). Abbreviations: FVIII:C, factor VIII:coagulant activity; PK, pharmacokinetics; SD, standard deviation; VWF:Ag, von Willebrand factor: antigen; VWF:CB, von Willebrand factor: collagen binding; VWF:RCo, von Willebrand factor: ristocetin cofactor.
Figure 3
Figure 3
Investigator’s efficacy assessment of treated bleeding events (A), minor and major bleeding events (including bleeding events without treatment) (B), and locations of bleeds (including bleeding events without treatment) (C) in both treatment arms.
See this image and copyright information in PMC

References

    1. Barr RD, Sek J, Horsman J, et al. Health status and health-related quality of life associated with von Willebrand disease. Am J Hematol. 2003;73(2):108–114. doi: 10.1002/ajh.10327 - DOI - PubMed
    1. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171–232. doi: 10.1111/j.1365-2516.2007.01643.x - DOI - PubMed
    1. Flood VH, Montgomery RR. von Willebrand disease: biologic diagnosis In: Lee CA, Berntorp EE, Hoots WK, editors. Textbook of Hemophilia. Oxford, UK: Wiley-Blackwell; 2010:294–301.
    1. Heijdra JM, Cnossen MH, Leebeek FWG. Current and emerging options for the management of inherited von Willebrand disease. Drugs. 2017;77(14):1531–1547. doi: 10.1007/s40265-017-0793-2 - DOI - PMC - PubMed
    1. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103–2114. doi: 10.1111/j.1538-7836.2006.02146.x - DOI - PubMed